A phase I, randomized, double-blind, two-way crossover study evaluating the safety, pharmacokinetics and pharmacodynamics of Biosimilar Filgrastim (EP2006) versus Filgrastim in healthy volunteers.

Trial Profile

A phase I, randomized, double-blind, two-way crossover study evaluating the safety, pharmacokinetics and pharmacodynamics of Biosimilar Filgrastim (EP2006) versus Filgrastim in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2015

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Sandoz
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top